CO6341571A2 - Composiciones y metodos de uso para anticuerpos terapeuticos - Google Patents

Composiciones y metodos de uso para anticuerpos terapeuticos

Info

Publication number
CO6341571A2
CO6341571A2 CO11005443A CO11005443A CO6341571A2 CO 6341571 A2 CO6341571 A2 CO 6341571A2 CO 11005443 A CO11005443 A CO 11005443A CO 11005443 A CO11005443 A CO 11005443A CO 6341571 A2 CO6341571 A2 CO 6341571A2
Authority
CO
Colombia
Prior art keywords
antibodies
compositions
methods
therapeutic antibodies
baffr
Prior art date
Application number
CO11005443A
Other languages
English (en)
Inventor
Christoph Heusser
Julia Neugebauer
Eveline Schaadt
Stefanie Urlinger
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09160323A external-priority patent/EP2127528A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6341571A2 publication Critical patent/CO6341571A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos que se enlazan específicamente al receptor de BAFF (BAFFR). De una manera más especifica, anticuerpos que son antagonistas del BAFFR, con actividad consumidora de células-B in vivo, y composiciones y métodos de uso para estos anticuerpos con el fin de tratar los trastornos patológicos que puedan ser tratados mediante la aniquilación o el consumo de las células-B, tales como lupus eritematoso sistémico o artritis reumatoide, u otras enfermedades autoinmunes o linfomas, leucemias, y mielomas.
CO11005443A 2008-07-17 2011-01-19 Composiciones y metodos de uso para anticuerpos terapeuticos CO6341571A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160323A EP2127528A1 (en) 2008-05-15 2009-05-15 Cup-Cake Toppers

Publications (1)

Publication Number Publication Date
CO6341571A2 true CO6341571A2 (es) 2011-11-21

Family

ID=40104736

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11005443A CO6341571A2 (es) 2008-07-17 2011-01-19 Composiciones y metodos de uso para anticuerpos terapeuticos

Country Status (3)

Country Link
US (3) US20160347851A1 (es)
CO (1) CO6341571A2 (es)
UA (1) UA103624C2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116294A1 (en) * 2017-12-15 2019-06-20 Creoptix Ltd. Assemblies and methods for screening sample fluids
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用

Also Published As

Publication number Publication date
UA103624C2 (ru) 2013-11-11
US20220298251A1 (en) 2022-09-22
US20160347851A1 (en) 2016-12-01
US20190135931A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
ECSP11010761A (es) Composiciones y métodos de uso para anticuerpos terapéuticos
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
DOP2013000260A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
ECSP11010932A (es) Compuestos de azaindazol como antagonistas del receptor de ccr1
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
AR054539A1 (es) Nuevos anticuerpos anti- madcam
EA201492272A1 (ru) Кристаллические формы модулятора андрогенных рецепторов
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
UY33651A (es) Anticuerpos anti-il12rbeta1 y su uso para tratar los trastornos autoinmunes e inflamatorios
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
EA201101572A1 (ru) Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2017002156A1 (es) Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
UY31340A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
EA201690880A1 (ru) Тетрациклические ингибиторы аутотаксина
GT200800052A (es) Compuestos triciclicos utiles como agonistas de recepciones de oxitocina
CO6341571A2 (es) Composiciones y metodos de uso para anticuerpos terapeuticos

Legal Events

Date Code Title Description
FG Application granted